LIVE WEBINAR: Thursday, July 18, 2024, 5:00 PM – 6:00 PM Eastern Time

Inside the Issue: Integrating ALK-Targeted Therapy into the Management of Localized Non-Small Cell Lung Cancer

A CME/MOC-Accredited Live Webinar

Join us on Thursday, July 18th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Faculty
Professor Solange Peters, MD, PhD
Director, Oncology
Chair, Thoracic Malignancies
Oncology Department
Lausanne University Hospital (CHUV)
Lausanne, Switzerland

Professor Ben Solomon, MBBS, PhD
Medical Oncologist
Head of Lung Medical Oncology Service
Peter MacCallum Cancer Centre
Melbourne, Australia

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Thursday, July 18, 2024
5:00 PM – 6:00 PM eastern time
Live CME/MOC-accredited webinar

Topics to Be Discussed

  • Significance of Biomarker Testing in Localized Non-Small Cell Lung Cancer (NSCLC) and Historical Management Paradigm for ALK-Positive Disease
  • Emerging Role and Practical Application of ALK-Targeted Therapy in Localized NSCLC

Target Audience
This activity is intended for medical oncologists, radiation oncologists, surgeons, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Convey the clinical relevance of a positive ALK testing result to patients with localized non-small cell lung cancer (NSCLC), and establish an algorithm to most effectively identify disease harboring these abnormalities.
  • Assess the anticipated benefits, risks and long-term outcomes associated with available neoadjuvant and adjuvant therapeutic strategies for localized NSCLC with ALK alterations, and consider this information when counseling patients regarding current treatment recommendations.
  • Evaluate published clinical research data with ALK-directed therapy as adjuvant treatment for localized ALK-positive NSCLC, and identify patients for whom this approach may be warranted.
  • Recognize adverse events associated with ALK-directed therapy for patients with localized NSCLC, and understand the supportive strategies available to minimize and/or manage these toxicities.

CE Credit
CME and ABIM MOC credit links will be emailed to each participant within 3 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1 Medical Knowledge MOC point toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Prof PetersAdvisory Committees and Consulting Agreements (All Fees to Institution): AbbVie Inc, Amgen Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BerGenBio ASA, Biocartis, BioInvent, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Daiichi Sankyo Inc, Debiopharm, Foundation Medicine, F-star Therapeutics Inc, Genentech, a member of the Roche Group, Genzyme Corporation, Gilead Sciences Inc, GSK, HUTCHMED, Illumina, Incyte Corporation, Ipsen Biopharmaceuticals Inc, iTeos Therapeutics, Janssen Biotech Inc, Lilly, Merck Serono, Merrimack Pharmaceuticals Inc, Mirati Therapeutics Inc, MSD, Novartis, Novocure Inc, Nykode Therapeutics, Pfizer Inc, PharmaMar, Promontory Therapeutics, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Takeda Pharmaceutical Company Limited; Contracted Research (Institutional Support): Principal investigator for trials sponsored by Amgen Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, iTeos Therapeutics, Mirati Therapeutics Inc, MSD, PharmaMar, Promontory Therapeutics, Seagen Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP; Speakers Bureaus (All Fees to Institution): AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Foundation Medicine, Genentech, a member of the Roche Group, GSK, Illumina, Ipsen Biopharmaceuticals Inc, Lilly, Mirati Therapeutics Inc, MSD, Novartis, Pfizer Inc, Sanofi, Takeda Pharmaceutical Company Limited. Prof SolomonAdvisory Committees: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Lilly, MSD, Pfizer Inc; Nonrelevant Financial Relationship: UptoDate.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

SURVEY PARTICIPANTSD Ross Camidge, MD, PhDAdvisory Roles: AbbVie Inc, AnHeart Therapeutics, Apollomics Inc, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, BeiGene Ltd, Bristol Myers Squibb, Coherus BioSciences, Daiichi Sankyo Inc, Dizal, Elevation Oncology, EMD Serono Inc, Genesis Therapeutics, Gilead Sciences Inc, Hummingbird Bioscience, Imagene AI, Immunocore, Janssen Biotech Inc, LianBio, Lilly, Medtronic Inc, Merck KGaA, Mirati Therapeutics Inc, Nalo Therapeutics, Newsoara, NextCure, OnKure Therapeutics, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi, Seagen Inc, Sutro Biopharma, Takeda Pharmaceuticals USA Inc, Theseus Pharmaceuticals, Xcovery; Company-Sponsored Trials at Institution (PI Roles): AbbVie Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Dizal, Genentech, a member of the Roche Group, Inhibrx, Karyopharm Therapeutics, Nuvalent, Pfizer Inc, Promontory Therapeutics Inc, Rain Oncology, Seagen Inc, Takeda Pharmaceuticals USA Inc, Turning Point Therapeutics Inc, Verastem Inc; Data Safety Monitoring Boards: BeiGene Ltd, Hengrui Therapeutics Inc; ILD Adjudication Committees: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Mersana Therapeutics Inc; Independent Data Monitoring Committees: BeiGene Ltd, Lilly, Mirati Therapeutics Inc, Takeda Pharmaceuticals USA Inc, Valence Pharma, Xencor; Scientific Advisory Boards: Apollomics Inc, Imagene AI; Scientific Review Committee: Apollomics Inc; Shares (Public Companies): Imagene AI, Kestrel Therapeutics, Tropocan; Steering Committee: AbbVie Inc. Jamie E Chaft, MDConsulting Agreements: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Genentech, a member of the Roche Group, Guardant Health, Janssen Biotech Inc, Merck, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Genentech, a member of the Roche Group, Merck, Novartis; Data and Safety Monitoring Board/Committee: Lilly. Ibiayi Dagogo-Jack, MD Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BostonGene, Bristol Myers Squibb, EpiQ, Foundation Medicine, Genentech, a member of the Roche Group, Lilly, Merus, Novocure Inc, Pfizer Inc, Roche Laboratories Inc, Sanofi, Thermo Fisher Scientific. Stephen V Liu, MDAdvisory Committees and Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Daiichi Sankyo Inc, Elevation Oncology, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Merck, Merus, Mirati Therapeutics Inc, Novartis, OSE Immunotherapeutics, Pfizer Inc, RAPT Therapeutics, Regeneron Pharmaceuticals Inc, Revolution Medicines, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: AbbVie Inc, Alkermes, AstraZeneca Pharmaceuticals LP, Elevation Oncology, Ellipses Pharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, Merck, Merus, Nuvalent, OSE Immunotherapeutics, Puma Biotechnology Inc, RAPT Therapeutics, Turning Point Therapeutics Inc; Data and Safety Monitoring Board/Committee: Candel Therapeutics.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by an educational grant from Genentech, a member of the Roche Group.